State Street Corp Buys 69,696 Shares of Pulse Biosciences, Inc. (NASDAQ:PLSE)

State Street Corp raised its position in shares of Pulse Biosciences, Inc. (NASDAQ:PLSE) by 17.8% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 461,333 shares of the company’s stock after buying an additional 69,696 shares during the quarter. State Street Corp’s holdings in Pulse Biosciences were worth $8,092,000 as of its most recent SEC filing.

A number of other large investors have also recently made changes to their positions in PLSE. Charles Schwab Investment Management Inc. raised its holdings in shares of Pulse Biosciences by 193.0% in the third quarter. Charles Schwab Investment Management Inc. now owns 148,114 shares of the company’s stock worth $2,598,000 after buying an additional 97,565 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC purchased a new stake in shares of Pulse Biosciences in the 3rd quarter worth $588,000. Creative Planning grew its position in shares of Pulse Biosciences by 113.9% during the 3rd quarter. Creative Planning now owns 21,910 shares of the company’s stock worth $384,000 after buying an additional 11,667 shares in the last quarter. Bank of New York Mellon Corp boosted its position in Pulse Biosciences by 23.4% during the 2nd quarter. Bank of New York Mellon Corp now owns 50,914 shares of the company’s stock valued at $570,000 after acquiring an additional 9,639 shares in the last quarter. Finally, Quest Partners LLC purchased a new position in Pulse Biosciences in the second quarter worth $91,000. 76.95% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Separately, StockNews.com raised shares of Pulse Biosciences to a “sell” rating in a research report on Tuesday.

Insider Transactions at Pulse Biosciences

In other Pulse Biosciences news, Director Robert W. Duggan acquired 55,256 shares of the firm’s stock in a transaction that occurred on Friday, December 13th. The shares were purchased at an average cost of $17.18 per share, for a total transaction of $949,298.08. Following the completion of the acquisition, the director now owns 42,328,717 shares of the company’s stock, valued at approximately $727,207,358.06. The trade was a 0.13 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CEO Burke Thomas Barrett sold 50,000 shares of the stock in a transaction that occurred on Wednesday, December 11th. The stock was sold at an average price of $17.42, for a total value of $871,000.00. Following the completion of the transaction, the chief executive officer now owns 63,172 shares of the company’s stock, valued at $1,100,456.24. The trade was a 44.18 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 71.50% of the company’s stock.

Pulse Biosciences Stock Down 3.8 %

Shares of PLSE opened at $18.02 on Friday. Pulse Biosciences, Inc. has a fifty-two week low of $6.59 and a fifty-two week high of $22.69. The business’s 50-day moving average is $18.01 and its two-hundred day moving average is $16.73.

Pulse Biosciences (NASDAQ:PLSE) last announced its earnings results on Wednesday, October 30th. The company reported ($0.21) earnings per share for the quarter. During the same period last year, the business earned ($0.19) earnings per share.

About Pulse Biosciences

Pulse Biosciences, Inc operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.